Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2000
10/18/2000CN1270587A New taxane derivatives
10/18/2000CN1270585A Substituted 1,2,3,4-tetrahydronaphthalene derivatives
10/18/2000CN1270529A Pharmaceutical compositions containing plasma protein
10/18/2000CN1270522A 13-Deoxyanthracycline derivatives and processes for preparing them
10/18/2000CN1270166A Derivatives of tricyclo-substituted isohydroxyloxime acid
10/18/2000CN1270062A Glycobiazole metal salt as synergist for radiotherapy or chemicotherapy and its preparing process and application
10/18/2000CN1270058A Medical composite powder for treating cancers
10/18/2000CN1270040A Anti-cancer Chinese-medicinal pill
10/18/2000CN1270032A Ultrasonic concentration-difference acid-alkali method for preparing doxorubicin hydrochloride lipid as injection
10/18/2000CN1270027A Stable aqueous solution of phthalylglutamic acidimide derivative
10/18/2000CN1057469C Anti-lung cancer medicine
10/17/2000US6133437 Antisense nucleic acid which is complementary to specific human and mouse nucleotide sequences and suppresses the biological activity of inhibitor of apoptosis in vitro; anticarcinogenic agents
10/17/2000US6133423 Don-1 gene and polypeptides and uses therefor
10/17/2000US6133419 Nucleotide sequences that encode phosphatidylinositol-3' kinase associated proteins and uses thereof
10/17/2000US6133312 Orally administering a synergistic tocotrienol and ionone mixture to inhibit tumor growth
10/17/2000US6133308 Synthesis of clasto-lactacystin beta-lactone and analogs thereof
10/17/2000US6133303 Various indene derivatives, with the exception of 5-(2-imidazole-1-yl-ethoxy)indan-1-one; treating cancer and treating or preventing restenosis or atherosclerosis
10/17/2000US6133280 Androgen synthesis inhibitors
10/17/2000US6133257 Fused polycyclic 2-aminopyrimidine derivatives
10/17/2000US6133243 Administering to tumor a complex consisting of liposomal viral dna, said viral dna being purified adenoviral dna not in an expression vector and lacking expressed viral oncoprotein that binds to functional p53 tumor suppressor protein
10/17/2000US6133238 Tetrahydrofurans
10/17/2000US6133032 Antisense modulation of PI3 kinase p110 beta expression
10/17/2000US6133031 Antisense inhibition of focal adhesion kinase expression
10/17/2000US6133024 Recombinant vector which codes for an rna capable of forming a triple helix with target nucleic acid; for transcription of the rna in target cells
10/17/2000US6133006 Nucleotide sequence coding an enzmatic polypeptide associated with signal transduction; for the diagnosis and treatment of osteoporosis, inflammation, skin disorders, asthma, nervous system disorders, cancer, eating disorders and infections
10/17/2000US6132987 Polypeptide associated with macrophages; for diagnosis and treatment of inflammation, arthritis and atherosclerosis
10/17/2000US6132980 Antibodies specific for TRP-2 a human tumor antigen recognized by cytotoxic T lymphocytes
10/17/2000US6132973 Nucleotide sequence coding protein associated with gene expression; for the diagnosis, prevention, and treatment of defects associated with cell proliferation
10/17/2000US6132730 Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment
10/17/2000US6132729 Coagulation-deficient tissue factor for use in effecting specific coagulation and for use in tumor treatment
10/17/2000US6132722 Recombinant antibody-enzyme fusion proteins
10/17/2000US6132720 Immunogens against gonadotropin releasing hormone
10/17/2000US6132718 Using a vaccine comprising antibodies and anti-idiotype antibodies that mimic an epitope of antigen that is associated with a tumor or infectious agent.
10/17/2000US6132713 Arginine deiminase derived from mycoplasma arthritidis and polymer conjugates containing the same
10/17/2000CA2178752C N-terminally chemically modified protein compositions and methods
10/17/2000CA2177357C Pna-dna-pna chimeric macromolecules
10/17/2000CA2117303C Anti-cancer immunotherapeutic vector constructs
10/17/2000CA2074533C 2-nitroimidazole derivative, production thereof, and radiosensitizer containing the same as active ingredient
10/13/2000CA2305047A1 2-pyridinylguanidine urokinase inhibitors
10/12/2000WO2000060109A1 Amplification of cyp24 and uses thereof
10/12/2000WO2000060100A1 Dsp-9 dual-specificity map kinase phosphatase
10/12/2000WO2000060099A1 Dsp-4 dual-specificity map kinase phosphatase
10/12/2000WO2000060098A1 Dsp-7 dual-specificity map kinase phosphatase
10/12/2000WO2000060082A2 Vesicle associated proteins
10/12/2000WO2000060080A2 Molecules of the immune system
10/12/2000WO2000060079A2 New members of tnf and tnfr families
10/12/2000WO2000060077A2 Compounds for therapy and diagnosis of lung cancer and methods for their use
10/12/2000WO2000060076A2 Compositions for the treatment and diagnosis of breast cancer and methods for their use
10/12/2000WO2000060055A1 Modified dendritic cells and uses therefor
10/12/2000WO2000060051A2 Arpe-19 as a platform cell line for encapsulated cell-based delivery
10/12/2000WO2000059967A1 Functionalized glycosaminoglycan polymer and medical instruments and drugs by using the same
10/12/2000WO2000059946A1 Hydroxymatairesinol in cancer prevention
10/12/2000WO2000059943A2 MONOCLONAL ANTIBODIES AGAINST HUMAN PROTEIN Mcm3, PROCESS FOR THEIR PRODUCTION, AND THEIR USE
10/12/2000WO2000059942A2 Human obesity protein binding protrein-2 homolog and uses thereof
10/12/2000WO2000059941A1 Purposeful movement of human migratory cells away from an agent source
10/12/2000WO2000059901A1 Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase
10/12/2000WO2000059899A1 Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them
10/12/2000WO2000059892A1 Pyrimidine compounds with pharmaceutical activity
10/12/2000WO2000059889A1 α-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES
10/12/2000WO2000059884A1 Pharmaceutically active compounds and methods of use thereof
10/12/2000WO2000059882A1 Anticancer calcium channel blockers
10/12/2000WO2000059881A1 Substituted azetidin-2-ones as cysteine protease inhibitors
10/12/2000WO2000059878A2 INHIBITORS OF LFA-1 BINDING TO ICAMs AND USES THEREOF
10/12/2000WO2000059874A1 NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE
10/12/2000WO2000059873A1 N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
10/12/2000WO2000059855A1 Ether compounds, compositions, and uses thereof
10/12/2000WO2000059548A1 Polyethyleneimine:dna formulations for aerosol delivery
10/12/2000WO2000059541A1 Preventives or remedies for cancer and method for screening the same
10/12/2000WO2000059518A2 Composition and method for inducing apoptosis in prostate cancer cells
10/12/2000WO2000059515A2 Immunomodulating polymers
10/12/2000WO2000059513A1 NON-CALCEMIC, ANTIPROLIFERATIVE, TRANSCRIPTIONALLY ACTIVE SULFUR-CONTAINING ANALOGS OF 1α, 25-DIHYDROXY VITAMIN D¿3?
10/12/2000WO2000059509A1 Phthalazine derivatives for treating inflammatory diseases
10/12/2000WO2000059495A1 (e)-styryl sulfone anticancer agents
10/12/2000WO2000059494A1 Styryl sulfone anticancer agents
10/12/2000WO2000059492A2 Anti-tumor activity of vitamin e, cholesterol, taxol and betulinic acid derivatives
10/12/2000WO2000059485A2 Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor
10/12/2000WO2000059484A2 Use of arylalkanoylpyridazines
10/12/2000WO2000059483A2 Transdermal drug delivery devices comprising a polyurethane drug reservoir
10/12/2000WO2000059482A1 Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants
10/12/2000WO2000059473A1 Compositions and methods for treating lymphoma
10/12/2000WO2000059448A2 Association of no-synthase inhibitor(s) and metabolic antioxidant(s)
10/12/2000WO2000035939A3 Connective tissue growth factor fragments and methods and uses thereof
10/12/2000WO2000035422A3 Method of administering a compound to multi-drug resistant cells
10/12/2000WO2000033880A3 Conjugate used for enriching in neuronal cells
10/12/2000WO2000033874A3 Boron neutron capture therapy using pre-targeting methods
10/12/2000WO2000033871A3 Use of human prostate tumour cell lines in cancer treatment
10/12/2000WO2000033869A3 Use of human prostrate cell lines in cancer treatment
10/12/2000WO2000032227A3 Ordered molecular presentation of antigens, method of preparation and use
10/12/2000WO2000023594A9 BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP)
10/12/2000WO2000020587A3 Cancer associated antigens and uses therefor
10/12/2000WO2000020446A3 Bax-mediated apoptosis modulating reagents and methods
10/12/2000WO2000020027A3 Methods for therapeutic vaccination
10/12/2000WO2000018440A9 Somatostatin receptor radioligand with increased uptake
10/12/2000WO1999064039A9 Bradykinin antagonists
10/12/2000WO1999041376A8 Retinoblastoma protein complexes and retinoblastoma interacting proteins
10/12/2000DE19915364A1 Verwendung von Arylalkanoylpyridazinen Use of Arylalkanoylpyridazinen
10/12/2000CA2369871A1 .alpha.-substituted carboxylic acid derivatives
10/12/2000CA2369446A1 Substituted azetidin-2-ones as cysteine protease inhibitors
10/12/2000CA2369071A1 Novel lipoic acid derivatives, their preparation, pharmaceutical use and pharmaceutical compositions cantaining them
10/12/2000CA2369005A1 Inhibitors of lfa-1 binding to icams and uses thereof
1 ... 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 1897 ... 2211